Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain.
Molecular Oncology Laboratory (CIBERONC), Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Hum Mutat. 2019 May;40(5):566-577. doi: 10.1002/humu.23732. Epub 2019 Mar 13.
There is still around 50% of the familial breast cancer (BC) cases with an undefined genetic cause, here we have used next-generation sequencing (NGS) technology to identify new BC susceptibility genes. This approach has led to the identification of RECQL5, a member of RECQL-helicases family, as a new BC susceptibility candidate, which deserves further study. We have used a combination of whole exome sequencing in a family negative for mutations in BRCA1/2 throughout (BRCAX), in which we found a probably deleterious variant in RECQL5, and targeted NGS of the complete coding regions and exon-intron boundaries of the candidate gene in 699 BC Spanish BRCAX families and 665 controls. Functional characterization and in silico inference of pathogenicity were performed to evaluate the deleterious effect of detected variants. We found at least seven deleterious or likely deleterious variants among the cases and only one in controls. These results prompt us to propose RECQL5 as a gene that would be worth to analyze in larger studies to explore its possible implication in BC susceptibility.
仍有约 50%的家族性乳腺癌(BC)病例的遗传原因尚未确定,在这里,我们使用下一代测序(NGS)技术来鉴定新的 BC 易感性基因。这种方法导致鉴定出 RECQL5,它是 RECQL-解旋酶家族的成员,是一个新的 BC 易感性候选基因,值得进一步研究。我们使用全外显子组测序结合 BRCA1/2 突变阴性的家族(BRCAX),在该家族中发现 RECQL5 中的一个可能有害的变体,然后对 699 个西班牙 BRCAX 家族和 665 个对照的候选基因的完整编码区和外显子-内含子边界进行靶向 NGS。对候选基因进行功能特征分析和致病变异的计算机预测,以评估检测到的变异的有害影响。我们在病例中发现了至少七个有害或可能有害的变体,而在对照中只有一个。这些结果促使我们提出 RECQL5 作为一个值得在更大的研究中分析的基因,以探索其在 BC 易感性中的可能作用。